GlobeNewswire by notified

Novotech Publishes Duchenne Muscular Dystrophy Landscape Report to Support Biotech Research Planning

Share

BOSTON, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Novotech, the global full-service clinical Contract Research Organization (CRO) that partners with biotech companies to accelerate the development of advanced and novel therapeutics at every phase, has released today an industry-leading report on Duchenne Muscular Dystrophy (DMD) Clinical Trial Landscape.

The report includes emerging genetic therapies, funding landscape, and a SWOT analysis designed to inform strategic drug development decision-making and ultimately enhancing the chances of successful and impactful treatments for DMD. The Novotech research analyst team provides these expert reports monthly, completely free of charge. These reports offer current insights into global clinical trial activity, revealing which regions experience the highest trial volumes and the factors behind these trends. They tackle the hurdles faced by biotech firms in specific therapeutic areas and discuss future paths in therapy and investment trends.

The Duchenne Muscular Dystrophy - Global Clinical Trial Landscape report examines the characterizations of DMD: it’s the most prevalent form of muscular dystrophy, it has a higher prevalence in males, the lack of dystrophin protein (caused by a mutation) leads to deterioration of muscle health, and the age DMD presents itself which is between 3-6 years. The disorder affects 1 in 5,000 live male births, with about 20,000 new global diagnoses annually, and is usually inherited through the mother, but 25% of cases occur spontaneously without any family history.

The report also focuses on the epidemiology, therapeutic challenges, and the evolving clinical trial trend data, including treatments and funding, offering invaluable insights for healthcare professionals and researchers. 

Management of the disease currently focuses on addressing symptoms and slowing disease progression whereas current research focuses more on therapeutic approaches including gene replacement, cell therapy, and membrane stabilization.

The global prevalence of this complex genetic disorder varies across regions. Europe leads with the highest prevalence, followed by North America, APAC and the Rest of World (ROW). Within Europe, countries such as Sweden, Norway, and Estonia present higher than-average rates of diagnosis at 16.7 and 16.2, and 12.8 cases per 100,000, respectively. In North America, Canada and the US sit at 10.6 and 10.2. In APAC China leads at 10.3 cases per 100,000.

Novotech’s research found there have been approximately 300 clinical trials initiated for DMD globally since 2019. North America leads in conducting trials (37%), followed by Asia Pacific (30%), Europe (24%) and ROW (9%). 

Key takeaways:

  • Analyzing patient recruitment trends since 2019 in single-country DMD clinical trials, where Europe consistently shows shorter recruitment durations and faster rates compared to the US and Asia Pacific. This may be attributed to streamlined regulatory processes, greater patient awareness, and more centralized healthcare systems.
  • There is a strong combination of public and venture-based funding for DMD out of the US in particular, but notable investments have been made in UK and South Korea as well, with the majority of funding concentrated on the preclinical stage.
  • Current research for DMD explores gene and RNA therapies with stand outs specifically for membrane stabilization techniques and interventions targeting secondary cascades as promising areas.
  • There is a robust DMD drug development pipeline with 28 drugs in preclinical stages, 14 in Phase I, 14 in Phase II, and 9 in Phase III.

This comprehensive resource guides healthcare professionals, researchers, and organizations in navigating the complex clinical trial DMD landscape. 

Download the report here

Media Contact
David James
mediacontact@novotech-cro.com
AU: +61 2 8218 2144 
USA: +1 415 951 3228
Asia: +65 3159 3427

About NovotechNovotech-CRO.com

Founded in 1997, Novotech is a global full-service clinical Contract Research Organization (CRO) focused on partnering with biotech companies to accelerate the development of advanced and novel therapeutics at every phase.

Recognized for its industry-leading contributions, Novotech has received numerous prestigious awards, including the CRO Leadership Award 2023, the Asia Pacific Cell & Gene Therapy Clinical Trials Excellence 2023, the Asia-Pacific Contract Research Organization Company of the Year Award since 2006.

The Company offers a comprehensive suite of services including laboratories, Phase I facilities, drug development consulting, regulatory expertise, and has experience with over 5,000 clinical projects, including Phase I to Phase IV clinical trials and bioequivalence studies. With a presence in 34 office locations and a dedicated team of 3,000+ professionals worldwide, Novotech is a trusted end-to-end strategic partner of choice.

For more information or to speak to an expert team member visit www.Novotech-CRO.com

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/50b76fdb-c279-440f-8d82-f98d366c7d03

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Magna Announces Date for Q1 2024 Results Call16.4.2024 00:00:00 CEST | Press release

AURORA, Ontario, April 15, 2024 (GLOBE NEWSWIRE) -- Magna International Inc. (TSX:MG) (NYSE:MGA) MAGNA INTERNATIONAL INC. FIRST QUARTER 2024 RESULTS WEBCAST FRIDAY – MAY 3, 2024 8:00 AM ET LIVE AUDIO WEBCAST Webcast registration: https://events.q4inc.com/attendee/510210737DIAL IN DETAILSParticipant Toll-Free Dial-In: Participant Toll Dial-In: Conference ID: 1-800-715-9871 1-646-307-1963 9829976Slide presentation will be available on our website Investors | Magna prior to the callREBROADCAST INFORMATION Replay available 2 hours after the call until May 10, 2024Toll-Free Dial-In: Toll Dial-In: Conference ID: 1-800-770-2030 1-609-800-9909 9829976 INVESTOR CONTACT Louis Tonelli, Vice-President, Investor Relations louis.tonelli@magna.com 905-726-7035 TELECONFERENCE CONTACT Nancy Hansford, Executive Assistant, Investor Relations nancy.hansford@magna.com 905-726-7108

Stevie® Awards Announce Winners in 18th Annual Stevie® Awards for Sales & Customer Service15.4.2024 23:09:08 CEST | Press release

FAIRFAX, Va., April 15, 2024 (GLOBE NEWSWIRE) -- Winners in the 18th annual Stevie® Awards for Sales & Customer Service, recognized as the world's top customer service awards and sales awards, were unveiled on Friday night at a gala ceremony in Las Vegas, Nevada USA, attended by more than 400 executives from around the world. The complete list of Stevie Winners by category is available at http://www.StevieAwards.com/Sales. The 10 most-honored organizations in the 2024 Stevie Awards for Sales & Customer Service received Grand (“best in show”) Stevie Award trophies. Nominees were not able to apply for Grand Stevie Awards directly. Winners were determined by a points system based on the total number of awards won, as well as having the highest average score in selected categories. DP DHL Worldwide, with 13 Gold, 18 Silver, and 14 Bronze Stevie Award wins, was the most honored organization this year, earning the top Grand Stevie Award trophy. In descending order, the organizations below we

World-Class Experts in Hospitality Investment Take the Stage at Questex’s IHIF EMEA 202415.4.2024 23:06:59 CEST | Press release

Event Takes Place 15-17 April at the InterContinental and Pullman hotels in Berlin LONDON, April 15, 2024 (GLOBE NEWSWIRE) -- Questex’s International Hospitality Investment Forum EMEA (IHIF EMEA) commenced with presentations from world-class experts in hospitality investment. The event takes place at the InterContinental and Pullman hotels in Berlin through 17 April 2024. With over 2,500 attendees attending IHIF EMEA 2024, it is one of the largest gatherings of industry professionals in the region. “Day one at IHIF is always energetic, and today was no different. With over 2,500 of the sector’s best and brightest arriving today there was a lot of networking, meetings, and excitement around the exhibition areas. The content sessions were all packed as speakers like James Pomeroy, HSBC, Elie Malouf, CEO IHG Hotels & Resorts, Mark Hoplamazian, CEO Hyatt Hotels, Federico Gonzalez, CEO Radisson Hotels, Sebastian Bazin, CEO Accor and Guy Verhofstadt former Prime Minister of Belgium spoke tod

Bombardier Completes Partial Redemption of US$100,000,000 of its 7.875% Senior Notes due 202715.4.2024 23:01:00 CEST | Press release

MONTRÉAL, April 15, 2024 (GLOBE NEWSWIRE) -- Bombardier Inc. (“Bombardier”) today announced that it has redeemed US$100 million principal amount of its outstanding 7.875% Senior Notes due 2027 (the “Redemption Notes”) as set forth in the notice of partial redemption issued March 14, 2024. “Bombardier’s continued focus on prioritizing debt and net leverage reduction has given our company momentum and enhanced flexibility,” said Bart Demosky, Executive Vice President and CFO, Bombardier. “This latest $100 million prepayment, deploying cash generated from operations, further underscores Bombardier’s commitment to improving its capital structure.” Payment of the redemption price and surrender of the Redemption Notes for redemption are being made through the facilities of the Depository Trust Company in accordance with the applicable procedures of the Depository Trust Company. This press release does not constitute an offer to sell or buy or the solicitation of an offer to buy or sell any s

HiddenA line styled icon from Orion Icon Library.Eye